Comparison between the effects of elective nodal irradiation and involved‐field irradiation on long‐term survival in thoracic esophageal squamous cell carcinoma patients: A prospective, multicenter, randomized, controlled study in China

Jiahua Lyu, Yisikandaer Abulimiti, Tao Li, Xiaozhi Zhang, Xiaohu Wang, Zhongge Tian, Long Chen, Bing Lü, Hong Chen, Jie Yang, Qifeng Wang, Jinnrong Zhang, Youguo Ma, Rui Liu, Aiguri Hage, Jinyi LangCancer 2020 · DOI

TL;DR

This study investigated whether a more targeted radiation approach (involved-field irradiation, IFI) could achieve similar long-term survival outcomes as a broader approach (elective nodal irradiation, ENI) in patients with thoracic esophageal squamous cell carcinoma (ESCC), while reducing treatment toxicity. The findings suggest that IFI is a viable alternative to ENI, offering comparable survival rates with potentially fewer side effects.

What Problem Does This Paper Address?

Esophageal cancer (EC) is a significant global health challenge, particularly in China. For patients who cannot undergo surgery, concurrent chemoradiotherapy (CCRT) is a standard treatment. A critical aspect of CCRT is the precise definition of the radiation target volume, especially concerning lymph node irradiation. Traditionally, elective nodal irradiation (ENI), which covers a larger area including potentially uninvolved lymph nodes, has been recommended. However, ENI is associated with higher rates of treatment-related toxicities like esophagitis and pneumonitis due to the larger radiation field. Involved-field irradiation (IFI), a more focused approach targeting only the gross tumor and clinically involved lymph nodes, theoretically offers reduced toxicity. While initial studies suggested IFI's toxicity benefits, there was a lack of high-quality evidence from randomized controlled trials to confirm its long-term survival efficacy compared to ENI. This study aimed to fill that gap by comparing the long-term survival outcomes of ENI and IFI in a prospective, multicenter, randomized trial.

Methods

This was a prospective, randomized, multicenter, controlled study. Patients with inoperable, histologically verified, Stage II-III thoracic esophageal squamous cell carcinoma (ESCC) were recruited. They were randomly assigned in a 1:1 ratio to either the elective nodal irradiation (ENI) arm or the involved-field irradiation (IFI) arm. Radiation therapy was delivered daily at 1.8-2.0 Gy per fraction, with a total dose of 60.0-66.0 Gy to the gross tumor volume and 50.0-54.0 Gy to the clinical target volume. The primary endpoints of acute treatment-related esophagitis and pneumonitis were reported previously. This article focuses on the secondary endpoints: overall survival (OS), progression-free survival (PFS), metastasis-free survival (MFS), and locoregional progression-free survival (LRFS).

Datasets

The study utilized data from 228 patients enrolled across nine participating centers in China between April 2012 and October 2016. These patients formed the dataset for the analysis. No new datasets were introduced.

Key Insights and Ideas

  • IFI as a Viable Alternative: The study provides strong evidence that IFI can achieve long-term survival outcomes comparable to ENI in thoracic ESCC patients. This is a significant finding as it suggests a way to potentially reduce treatment toxicity without compromising efficacy.
  • Toxicity-Efficacy Trade-off Re-evaluated: While ENI has been the standard due to concerns about microscopic disease spread, this study challenges the necessity of its broader field for survival. The findings suggest that the benefits of reduced toxicity with IFI may outweigh the theoretical risks of missing microscopic disease in certain elective nodal regions.
  • Incidental Dose Hypothesis: The authors propose that IFI might still deliver a considerable incidental dose to elective nodal regions, potentially contributing to tumor control. This highlights the complex interplay of radiation fields and their effects on both tumor and surrounding tissues.
  • Immune System Modulation: The concurrent chemotherapy used in this study, combined with radiotherapy's potential to stimulate immune responses, might play a role in achieving similar survival outcomes with IFI. This opens avenues for further research into the immunomodulatory effects of different radiation strategies.

Key Results

  • Overall Survival (OS): The median OS for the entire cohort was 33.8 months. Specifically, median OS was 32.5 months for the ENI group and 34.9 months for the IFI group (P = .941), showing no significant difference. 5-year OS rates were 29.8% for ENI and 30.7% for IFI.
  • Progression-Free Survival (PFS): The median PFS for the entire cohort was 21.0 months. Median PFS was 20.3 months for ENI and 21.4 months for IFI (P = .809), again showing no significant difference. 5-year PFS rates were 26.9% for ENI and 27.4% for IFI.
  • Metastasis-Free Survival (MFS): Median MFS was 28.2 months for ENI and 26.0 months for IFI (P = .983).
  • Locoregional Progression-Free Survival (LRFS): Median LRFS was 25.0 months for ENI and 26.6 months for IFI (P = .598).
  • Toxicity: While not the primary focus of this paper, previous results indicated significantly lower rates of grade ≥2 esophagitis and pneumonitis in the IFI group compared to the ENI group.
  • Multivariate Analysis: Tumor response and clinical stage were identified as independent predictors of OS. Tumor location, clinical stage, and tumor response were independent factors influencing PFS. The treatment group (ENI vs. IFI) was not an independent predictor for either OS or PFS.

Limitations and Future Work

  • Limitations: The authors acknowledge that this is the first prospective, multicenter, randomized study of its kind, and further validation from other studies would be beneficial. While the study found no significant difference in survival, the potential for IFI to miss microscopic disease in certain elective nodal regions remains a theoretical concern, although the study suggests this may not translate to worse outcomes. The study also involved concurrent chemotherapy, which could influence the observed outcomes.
  • Future Work: The authors suggest that given the comparable survival rates and reduced toxicity, IFI should be considered an acceptable therapeutic alternative for thoracic ESCC. Further research could explore the precise mechanisms by which IFI achieves similar efficacy, potentially involving incidental nodal irradiation and immune system modulation. Investigating optimal IFI strategies and their long-term impact on quality of life would also be valuable.

Summary updated

Abstract

IFI was associated with similar survival as ENI in patients with thoracic ESCC, suggesting that IFI is an acceptable treatment method for thoracic ESCC.
BibTeX
@inproceedings{lyu2020comparison,
  author = {Jiahua Lyu and Yisikandaer Abulimiti and Tao Li and Xiaozhi Zhang and Xiaohu Wang and Zhongge Tian and Long Chen and Bing Lü and Hong Chen and Jie Yang and Qifeng Wang and Jinnrong Zhang and Youguo Ma and Rui Liu and Ruifeng Liu and Aiguri Hage and Jinyi Lang},
  title = {{Comparison between the effects of elective nodal irradiation and involved‐field irradiation on long‐term survival in thoracic esophageal squamous cell carcinoma patients: A prospective, multicenter, randomized, controlled study in China}},
  booktitle = {Cancer},
  year = {2020},
  doi = {10.1002/cam4.3409},
}
Figure